Pharmacotherapy & Pipeline

Weight Loss, GLP-1 Therapy, & Gallstone Prevention

Rapid weight loss has always caused gallstones. GLP-1s add two more mechanisms on top of that — and the same prevention tool, at the same dose, works.

Content by Douglas Maready, MD

By the numbers

34%

of diabetic patients on a GLP-1 RA developed gallstones on ultrasound over 24 months.

Salem A et al., Am J Gastroenterol, 2024

Core Concepts

Six ideas that reframe how you think about gallstones during weight loss.

Click any card for a quick reference summary with key pearls and references.

Epidemiology & Risk

Who gets stones, why they form, and why obesity + rapid weight loss is the double-hit every clinician sees in clinic.

Read pearls

The 1.5 kg/week Threshold

Weinsier 1995's exponential curve — below 1.5 kg/wk, risk is minimal. Above it, the rate climbs sharply.

Read pearls

The GLP-1 Three-Hit

Supersaturated bile + suppressed CCK secretion + blunted CCK response. Three independent insults, not one.

Read pearls

Landmark Prevention RCTs

Shiffman 1995 (VLCD) and Sugerman 1995 (RYGB) — why 600 mg ursodiol became the standard dose.

Read pearls

The GLP-1 Biliary Signal

He 2022, Mishra 2023, Salem 2024 — what the meta-analyses and real-world cohorts actually show.

Read pearls

The Symptom Overlap Pitfall

GLP-1 GI side effects mirror gallstone symptoms almost exactly. The patient you think is just tolerating the drug may have biliary disease.

Read pearls

Clinical Algorithms

Procedural walkthroughs that deserve a full screen.

These open dedicated deep dives with trial-by-trial data and step-by-step protocols.

Gallstone Incidence, Trial-by-Trial

STEP 1, STEP 3, STEP 5, SCALE, SURMOUNT, Retatrutide, Salem 2024 — the actual numbers, in one place.

Open walkthrough

Ursodiol Prevention Protocol

Who to treat, how to dose, how long, and what to monitor. Mechanism, contraindications, and guideline support.

Open walkthrough

Disclosures

This is a teaching summary for clinicians. References throughout the page link to peer-reviewed primary literature, clinical trial reports, and published guidelines. Ursodiol (ursodeoxycholic acid) is available as a generic; branded formulations are also available. For clinical decisions, consult current guidelines and full prescribing information.

Epidemiology

Who Gets Gallstones

Cholelithiasis is common, complications are common, and obesity sits at the center of the modern risk picture.

10–20% of adults harbor gallstones; ~750,000 cholecystectomies per year in the U.S.
40% of patients >40 years develop symptoms or complications over time
Classic risk factors: female sex, Hispanic ethnicity, obesity, T2DM, pregnancy/postpartum, rapid weight loss
Metabolic syndrome doubles risk; each additional MetS criterion adds incremental risk (Chen 2012)
~80% of stones are asymptomatic — most trials capture only the 20% who present clinically
~35% with symptomatic stones will eventually need cholecystectomy

Bottom line

In a medical weight-management clinic, almost every patient walks in with a risk factor profile already stacked toward gallstones. Weight loss is additive — not the starting point.

References

Lammert F, Miquel JF. J Hepatol. 2008;48:S124-S135.

Chen LY et al. World J Gastroenterol. 2012;18(31):4215-4220.

Schirmer B et al. J Long Term Eff Med Implants. 2005:329-338.

Rate of Loss

The 1.5 kg/week Threshold

Weinsier pooled nine cohorts from five weight-loss trials and demonstrated an exponential rise in gallstone risk above ~1.5 kg/week.

Below 1.5 kg/week: gallstone incidence ~0.3–0.5% of subjects per week
Above 1.5 kg/week: incidence jumps to 1.6–3.2% per week — a 4–10× inflection
Shiffman 1995 VLCD cohort: 30% of women on placebo developed stones by week 16
Stones form preferentially early, within the first 1–4 months of rapid loss
Rate, not magnitude, is what drives the risk — 15% loss over a year looks very different from over 4 months
Early titration on semaglutide 2.4 mg or tirzepatide 15 mg easily pushes high-responders above this threshold

Bottom line

The curve bends sharply at 1.5 kg/week. Individual high-responders on GLP-1s routinely cross this line during the first 8–16 weeks — exactly when CCK mechanisms compound the risk.

References

Weinsier RL, Wilson LJ, Lee J. Am J Med. 1995;98(2):115-117.

Shiffman ML et al. Ann Intern Med. 1995;122(12):899-905.

Pathophysiology

The GLP-1 Three-Hit

GLP-1 gallstone risk isn't just "rapid weight loss again." It's additive — three independent insults to the same system.

Hit 1 — Supersaturated bile: rapid weight loss mobilizes adipose cholesterol; hepatic secretion exceeds bile's solubilizing capacity
Hit 2 — CCK secretion drops: GLP-1 infusion suppresses postprandial CCK release in healthy and diabetic subjects (Rehfeld 2018)
Hit 3 — CCK response is blunted: exenatide halved gallbladder ejection fraction to exogenous CCK (29% vs 46%; Keller 2012)
De facto low-fat intake on GLP-1s (patients self-restrict fat) removes the natural CCK stimulus
Delayed gastric emptying spreads fat delivery, further dampening peak CCK signaling
Net effect: bile gets more cholesterol-saturated AND the gallbladder stops emptying it

Bottom line

Stasis plus supersaturation is the classical recipe for stones. GLP-1s engineer both conditions simultaneously — which is why the biliary signal tracks across the class.

References

Keller J et al. Regul Pept. 2012;179(1-3):77-83.

Rehfeld JF et al. Scand J Gastroenterol. 2018;53(12):1429-1432.

Stokes CS et al. Clin Gastroenterol Hepatol. 2014;12(7):1090-1100.

Landmark Prevention RCTs

Shiffman & Sugerman (1995)

The two trials that established 600 mg/day as the ursodiol dose that works — in diet and in surgery.

Shiffman 1995 (n=1004, 16-wk VLCD): placebo 30% women/25% men developed stones; 600 mg reduced to 1.5%/7%
Sugerman 1995 (n=312, post-RYGB): placebo 32%, 300 mg 13%, 600 mg 2%, 1200 mg 6%
600 mg is the efficacy plateau — no incremental benefit at 1200 mg
Ying 2022 meta-analysis (17 studies, 4054 post-bariatric patients): OR 0.20 (0.16–0.25)
Stokes 2014 meta (11 trials): ursodiol cut stones from 19%→3% in diet trials and 28%→9% post-bariatric
Lind 2025 real-world: cholecystectomy after bariatric surgery dropped from 2.9% to 0.5% with 600 mg × 6 months

Bottom line

600 mg/day for the duration of active rapid weight loss is the dose supported by the cleanest dose-response data in the literature. The bariatric evidence is Grade A / BEL 1.

References

Shiffman ML et al. Ann Intern Med. 1995;122(12):899-905.

Sugerman HJ et al. Am J Surg. 1995;169(1):91-97.

Stokes CS et al. Clin Gastroenterol Hepatol. 2014;12(7):1090-1100.

Ying J et al. Obesity. 2022;30(6):1170-1180.

Lind R et al. Surg Laparosc Endosc Percutan Tech. 2025;35(3).

Modern Evidence

The GLP-1 Biliary Signal

What the meta-analyses and real-world cohorts actually show — across the class, not just one agent.

He 2022 (76 RCTs, 103,371 pts, JAMA IM): GLP-1 RAs raise gallbladder/biliary disease RR 1.37, cholecystitis 1.36, cholecystectomy 1.70
Per-agent signal strongest with liraglutide (RR 1.79); present for dulaglutide, exenatide, SC semaglutide
Mishra 2023 (10 tirzepatide trials, 6836 pts): cholelithiasis 0.21% placebo vs 0.5–1% on tirzepatide; ANOVA p=0.008
Salem 2024 (229 T2DM, 24-month US surveillance): 34% developed gallstones; OR 2.1 for GLP-1 use
Risk amplifiers at baseline: MetS, high triglycerides, obesity, prediabetes
Risk amplifiers on therapy: rapid weight loss (first 16–24 weeks), high-dose titration

Bottom line

The class-level biliary signal is real and reproducible. In symptomatic surveillance, incidence looks modest (1–3%); under active imaging (Salem), it's an order of magnitude higher. The truth is probably in between, and much higher than reported trial numbers suggest.

References

He L et al. JAMA Intern Med. 2022;182(5):513-519.

Mishra R et al. J Endocr Soc. 2023;7(7):bvad097.

Salem A et al. Am J Gastroenterol. 2024;119(Suppl):S2100.

Clinical Pitfall

The Symptom Overlap

The GLP-1 GI side-effect list and the gallstone symptom list are almost identical. Partial-obstruction symptoms can be transient, which makes biliary disease look like "just the drug."

GLP-1 GI side effects: nausea, vomiting, abdominal pain, dyspepsia, bloating, eructation, GERD
Gallstone symptoms: RUQ pain, N/V, belching, bloating, dyspepsia — same list minus GERD
Biliary symptoms can be transient (intermittent partial obstruction) — patients self-report as "a rough day on the pen"
RUQ pain, post-prandial pain, fatty-food intolerance, or fever → ultrasound, not dose reduction
80% of stones are asymptomatic — low threshold for imaging in high-risk patients during early weight loss
Patients post-cholecystectomy can still have biliary duct disease; symptoms don't rule out stones

Bottom line

Before attributing persistent GI symptoms to "just GLP-1 tolerability," get an ultrasound. A quiet biliary event in the rapid-loss window is the most common miss in modern medical weight management.

References

Jones MW, Weir CB, Ghassemzadeh S. Gallstones (Cholelithiasis). StatPearls Publishing; 2020.

Abraham S et al. Am Fam Physician. 2014;89(10):795-802.

Gallstones & GLP-1 / Trial-by-Trial Incidence

Clinical Algorithm

Gallstone Incidence, Trial-by-Trial

What the actual placebo-vs-treatment gallstone numbers look like across the GLP-1/GIP/glucagon pipeline — and the historical weight-loss RCTs that anchor them. Click to expand each trial.

Historical: Rapid Weight Loss (Diet & Surgery)

01Shiffman 1995 — VLCD Prevention RCT (n=1004)

16-week, 520 kcal/day HMR liquid-protein diet; BMI >38; normal gallbladder US at baseline.

Placebo: 30% (women) / 25% (men) developed stones

300 mg ursodiol: 9% / 6%

600 mg ursodiol: 1.5% / 7%

1200 mg ursodiol: 3% / 0%

600 mg emerges as the efficacy plateau.

02Sugerman 1995 — Post-RYGB RCT (n=312)

Multicenter, double-blind; ursodiol started on post-op day 4; ultrasound at 2, 4, and 6 months.

6-month gallstone formation rates:

Placebo: 32% · 300 mg: 13% · 600 mg: 2% · 1200 mg: 6%

Cleanest dose-response in the prevention literature. Most stones formed within the first 2–4 months.

03Weinsier 1995 — Rate-of-Loss Meta-Analysis

Pooled 9 cohorts from 5 trials; derived "% subjects/week" normalized metric plotted against rate of loss (kg/week).

Finding: exponential rise in gallstone risk when weight loss exceeds ~1.5 kg/week (adjusted r² = 0.98).

Below threshold: 0.3–0.5% per week. Above threshold: 1.6–3.2% per week.

This is the curve the entire modern prevention literature is drawn on top of.

GLP-1 Monoagonists

04STEP 1 — Semaglutide 2.4 mg (Wilding 2021)

68-week phase 3 in adults with overweight/obesity without diabetes; n=1961.

Gallbladder-related disorders (mostly cholelithiasis): 2.6% semaglutide vs 1.2% placebo.

Hepatobiliary SAEs: 1.3% vs 0.2% — the largest single driver of the SAE gap between arms.

05STEP 3 — Semaglutide + Intensive Behavioral Therapy (Wadden 2021)

68-week phase 3 with intensive lifestyle background; high weight loss per group.

Gallbladder-related disorders: 4.9% semaglutide vs 1.5% placebo — highest of the STEP series, consistent with highest-magnitude weight loss.

06STEP 5 — Semaglutide 2.4 mg, 2-Year Data (Garvey 2022)

104-week phase 3; n=304; 92.8% completion.

Gallbladder-related disorders: 2.6% semaglutide vs 1.3% placebo.

Risk does NOT accumulate linearly — most events cluster in the first year during the rapid-loss phase, then plateau.

07SCALE Obesity & Prediabetes — Liraglutide 3.0 mg (Pi-Sunyer 2015)

56-week phase 3; n=3731 randomized.

Gallbladder-related events: 2.5% liraglutide (3.1 events/100 pt-yrs) vs 1.0% placebo (1.4 events/100 pt-yrs).

78% of cholelithiasis/cholecystitis events in the liraglutide arm went to cholecystectomy.

Participants with events had above-average weight loss — the rapid-loss mechanism again.

GLP-1 / GIP Dual Agonist

08SURMOUNT-1 / SURMOUNT-2 — Tirzepatide (Jastreboff 2022, Garvey 2023)

SURMOUNT-1: 72-week phase 3 in adults with obesity without diabetes (n=2539). SURMOUNT-2: same in adults with T2DM (n=938).

SURMOUNT-1 cholelithiasis: 2.5% tirzepatide vs 1.0% placebo.

Pooled SURMOUNT-1 + SURMOUNT-2: cholelithiasis 1.1% vs 1.0% · cholecystitis 0.7% vs 0.2%.

Acute gallbladder events clustered in patients with the greatest weight reduction.

09Mishra 2023 — Tirzepatide 10-Trial Meta-Analysis (n=6836)

Pooled single-arm proportions; ANOVA across four arms (placebo, 5/10/15 mg).

Cholelithiasis: placebo 0.21% · 5 mg 0.95% · 10 mg 0.53% · 15 mg 0.52% (ANOVA p=0.008).

Signal is real; dose-response is non-monotonic (small event counts). Pancreatitis rates did NOT differ — reassuring counter-signal.

Lipase elevation was the only monotonic dose-response, but wasn't accompanied by clinical pancreatitis.

Triple Agonist (GLP-1 / GIP / Glucagon)

10Retatrutide Phase 2 — Jastreboff 2023 (NEJM)

48-week phase 2 in adults with obesity; retatrutide 1/4/8/12 mg vs placebo; n=338.

Peak weight loss: -24.2% at 12 mg — steepest trajectory of any agent to date.

Gallbladder AEs: cholelithiasis reported in 2 participants; cholecystitis in 1. No unique gallbladder signal in the published phase 2 data — though small event counts and short follow-up limit inference.

Caveat: given the magnitude and velocity of weight loss, the phase 3 (TRIUMPH) and longer-term data will be the meaningful test. Expect a rapid-loss-driven biliary signal in larger samples.

GLP-1 Class Meta-Analyses & Real-World Data

11He 2022 — Class-Level GLP-1 Meta-Analysis (JAMA IM)

76 RCTs; 103,371 patients. Head-to-head comparison of GLP-1 RAs vs controls for biliary outcomes.

Any gallbladder/biliary disease: RR 1.37 (1.23–1.55), ARD 27 per 10,000 person-years.

Cholelithiasis: RR 1.27 (1.10–1.47).

Cholecystitis: RR 1.36 (1.14–1.62).

Cholecystectomy: RR 1.70 (1.25–2.32).

Per-agent: liraglutide RR 1.79 · dulaglutide 1.35 · exenatide 1.23 · SC semaglutide 1.28 (borderline).

Risk amplified at higher doses, longer durations, and when used for weight loss rather than glycemic control.

12Salem 2024 — 24-Month Prospective Ultrasound Cohort

n=229 T2DM patients on GLP-1 RAs followed prospectively with US at 6, 12, 18, 24 months.

34% developed gallstones over 24 months. OR 2.1 for GLP-1 exposure.

Incidence by subgroup: diabetes >10 yrs 44.6% · BMI >30 39.8% · liraglutide 35.7% · semaglutide 31.6%.

Caveat: conference abstract (Am J Gastroenterol. Oct 2024), not yet peer-reviewed manuscript. But the ultrasound surveillance design is what makes the 34% figure far higher than symptom-based trial reporting.

Final synthesis

Symptom-based trial surveillance consistently shows 1–5% excess gallbladder events on GLP-1 therapy vs placebo. Active ultrasound surveillance shows it's closer to 1 in 3. Historical rapid-weight-loss data (Shiffman, Sugerman) is mechanistically identical, runs at 25–32% placebo incidence over short windows, and is neatly prevented by 600 mg ursodiol. The prevention paradigm ports cleanly onto the GLP-1 era.

Gallstones & GLP-1 / Ursodiol Protocol

Pharmacotherapy

Ursodiol Prevention Protocol

Who to treat, how to dose, how long, and what to watch for. Guideline-backed for bariatric surgery, extrapolated for GLP-1-driven rapid weight loss.

Mechanism

Shifts Bile Chemistry

Cholesterol precipitating → solubilizing

+ Changes bile to a cholesterol-solubilizing milieu

+ Suppresses hepatic cholesterol synthesis & secretion

Improves Biliary Flow

Choleretic action, reduced stasis

+ Increases bile flow

+ Inhibits intestinal cholesterol absorption

Kinetics

t½ ~100 hrs; steady state at 3 weeks

+ Long half-life supports once-daily dosing

– Constitutes 30–60% of bile acid pool with chronic use

What It Doesn't Do

Not a universal stone-buster

– No effect on calcified or pigment stones

– Does not replace cholecystectomy in symptomatic disease

Dosing

Prevention (Rapid Weight Loss)

Label indication · supports bariatric + medical weight loss

+ 600 mg PO daily (or 300 mg BID) — evidence-based prevention dose

+ Supported by Sugerman 1995 dose-response plateau

– Safety beyond 24 months of continuous use not established

ASMBS 2019 Bariatric Guidance

Grade A · BEL 1 recommendation

+ Sleeve gastrectomy: ursodiol 500 mg QD

+ RYGB or BPD-DS: ursodiol 300 mg BID

– Doses slightly below the 600 mg prevention studies; both are supported

Dissolution (existing stones)

Different indication, different dose

+ 8–10 mg/kg/day in 2–3 divided doses

– Only for radiolucent, non-calcified stones <20 mm

Duration

Aligns with the rapid-loss window

+ Start at initiation of titration or surgery

+ Continue 6 months (or through weight plateau)

– Reassess at 6–12 months; extend if still in active loss

Who to Treat

Strong Candidates

Stacking risk factors = clear indication

+ Post-bariatric surgery (any type) × 6 months

+ High-dose GLP-1/GIP with rapid loss (>1.5 kg/wk) in first 16–24 wks

+ VLCD programs (<800 kcal/day)

+ Prior symptomatic biliary disease + continued weight loss

Reasonable Candidates

Shared decision-making zone

+ Baseline MetS + incretin initiation

+ Hispanic ethnicity + rapid loss

+ Female sex, age <50, BMI ≥30 on titration

Not Candidates

Contraindicated or not useful

– Calcified, radiopaque, or pigment stones

– Allergy to bile salts

– Compelling reason for cholecystectomy already present

Post-Cholecystectomy

Clinical judgment

– Primary indication (stone prevention) no longer applies

+ Choledocholithiasis still possible — address symptoms promptly

Tolerability (600 mg/day)

Ursodiol vs Placebo (>2% difference)

Pivotal prevention trials · N=647

+ Nausea/vomiting, diarrhea — mostly mild

+ Generally well tolerated at 600 mg

– Constipation, alopecia, dizziness, back pain reported

Monitoring

Low-touch; no required labs

+ Monitor for new RUQ pain, fatty-food intolerance

+ Ultrasound if symptomatic during titration

– Not established beyond 24 months of use

Practical synthesis

600 mg/day during the rapid-weight-loss window (first 6 months of bariatric surgery OR GLP-1 titration to maintenance) is the defensible prevention dose. The bariatric evidence is Grade A; extrapolation to GLP-1s rests on identical rapid-loss physiology plus the GLP-1-specific CCK mechanisms. Reassess at 6 months; discontinue once weight has plateaued.

References

Sugerman HJ et al. Am J Surg. 1995;169(1):91-97.

Shiffman ML et al. Ann Intern Med. 1995;122(12):899-905.

Stokes CS et al. Clin Gastroenterol Hepatol. 2014;12(7):1090-1100.

Ying J et al. Obesity. 2022;30(6):1170-1180.

Lind R et al. Surg Laparosc Endosc Percutan Tech. 2025;35(3).

Mechanick JI et al. (AACE/TOS/ASMBS/OMA/ASA 2019). Endocr Pract. 2019;25(12):1346-1359.

Ursodiol [package insert / USP monograph]. Current prescribing information.